Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era

Chen, Yen‐Ching; Page, John H.; Chen, Rong; Giovannucci, Edward

doi:10.1002/pros.20825

Cited by 65 publications

(80 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…the grandfathers) were alive. It is important to ascertain family history in SDR in addition to FDR because, although cancer risk estimation has been based mainly on family history among FDR [8,9], family history among SDR may be informative in cancer risk assessment, particularly for sex-specific cancers, such as breast and prostate.…”

Section: Discussionmentioning

confidence: 99%

“…Approximately 1.44 million new cases of invasive, non-skin cancers are estimated to have occurred in 2008 [1]. Site-specific cancer risk factors are not completely established and vary widely; however, a positive family history is a known risk factor for most malignancies [2,3,4,5,6,7,8,9]. Hereditary cancer syndromes, usually characterized by significant family history, account for only a small percentage of all cancer cases [10].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of Family History of Breast, Colorectal, Prostate, and Lung Cancer in a Population-Based Study

Mai¹,

Wideroff²,

Greene³

et al. 2010

Public Health Genomics

View full text Add to dashboard Cite

Background: A positive family history is a known risk factor for several cancers; thus, obtaining a thorough family cancer history is essential in cancer risk evaluation and prevention management. Methods: The Family Health Study, a telephone survey in Connecticut, was conducted in 2001. A total of 1,019 participants with demographic information and family cancer history were included in this study. Prevalence of a positive family history of breast, colorectal, prostate, and lung cancer for first- and second-degree relatives was estimated. Logistic regression was used to compare prevalence by demographic factors. Results: A positive family history among first-degree relatives was reported by 10.9% (95% Confidence Interval, CI = 8.8–13.3) of respondents for breast cancer, 5.1% (95% CI = 3.9–6.7) for colorectal cancer, 7.0% (95% CI = 5.2–9.4) for prostate cancer, and 6.4% (95% CI = 4.9–8.3) for lung cancer. The reported prevalence of family history of specific cancers varied by sex, age and race/ethnicity of the respondents. Conclusion: Family history prevalence for 4 of the most common adult solid tumors is substantial and the reported prevalence varied by respondent characteristics. Additional studies are needed to evaluate tools to promote accurate reporting of family history of cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prevalence of Family History of Breast, Colorectal, Prostate, and Lung Cancer in a Population-Based Study

Mai¹,

Wideroff²,

Greene³

et al. 2010

Public Health Genomics

View full text Add to dashboard Cite

show abstract

“…It is possible that as testosterone activates PSA transcription, the levels of testosterone generated by hormone treatment might be sufficient to induce PSA promoter transcription in bladder, and therefore CRE expression, and might thus activate Pim1 expression. This theory is supported by evidence that PSA is expressed in some bladder carcinomas [52][53][54].…”

Section: Discussionmentioning

confidence: 80%

Pim1 Kinase Cooperates with Hormone Treatment to Promote Bladder and Ureteral Urothelial Hyperplasia

Narlik-Grassow¹,

Blanco‐Aparicio

Yol³

et al. 2014

J Carcinog Mutagen

View full text Add to dashboard Cite

The Pim serine/threonine kinases have been shown to be overexpressed in cancer. Elevated levels of Pim1 kinase were demonstrated in human leukemia and lymphomas, as well as in solid tumors such as pancreatic, prostate and bladder cancers, and have been proposed as a prognostic marker. Although the Pim kinases have been identified as oncogenes in transgenic mouse models, they have only weak transforming abilities on their own. However, they have been shown to greatly enhance the ability of other genes or chemical carcinogens to induce tumors. To explore the role of Pim1 in bladder and ureteral urothelial cancer, we generated a conditional Pim1 transgenic mouse model and found that prostate specific antigen-(PSA)-driven Cre expression lead to transgene expression in the bladder upon (testosterone/estrogen) hormone treatment. We then explored the effect of Pim1 overexpression on hormone treatment, either alone or in combination with Pten haploinsufficiency. We found that Pim1 overexpression increased the severity of bladder and ureteral urothelial hyperplasias in both backgrounds, leading to pyelonephritis in transgenic animals. Our data suggest that Pim1 might contribute to progression, rather than initiation, and that the hyperplasias also contribute to the development of pyelonephritis.

show abstract

“…Not only a family history of prostate cancer but also breast/ ovarian cancer increase the risk for men in a given familial line. In such case the relative risk is 1.7 and in the case of incidence of PC together with breast or ovarian cancer, the risk is 5.8 but results from other studies differ [14][15][16] . Segregate studies have found a mostly autosomal dominant heredity in patients with sporadic and familial prostate cancer.…”

Section: -45mentioning

confidence: 84%

Genetic Determinants of Prostate Cancer: A Review

Král¹,

Rosinska²,

Študent³

et al. 2011

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era

Abstract: Background-A family history of prostate cancer (PCa) or breast cancer (BCa) has been associated with the risk of PCa, but the risks were inconsistent in terms of the affected family members, and data in the PSA era are limited.

Cited by 65 publications

References 45 publications

Prevalence of Family History of Breast, Colorectal, Prostate, and Lung Cancer in a Population-Based Study

Prevalence of Family History of Breast, Colorectal, Prostate, and Lung Cancer in a Population-Based Study

Pim1 Kinase Cooperates with Hormone Treatment to Promote Bladder and Ureteral Urothelial Hyperplasia

Genetic Determinants of Prostate Cancer: A Review

Contact Info

Product

Resources

About